Thomas Patrick Kelly Sells 5,000 Shares of Deciphera Pharmaceuticals Inc (DCPH) Stock

Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) CFO Thomas Patrick Kelly sold 5,000 shares of the stock in a transaction dated Monday, January 7th. The shares were sold at an average price of $25.18, for a total value of $125,900.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Shares of DCPH stock opened at $25.89 on Friday. The company has a quick ratio of 18.46, a current ratio of 18.46 and a debt-to-equity ratio of 0.06. Deciphera Pharmaceuticals Inc has a 12 month low of $18.55 and a 12 month high of $45.61. The company has a market capitalization of $956.97 million, a price-to-earnings ratio of -8.66 and a beta of 3.38.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last announced its quarterly earnings data on Thursday, November 8th. The company reported ($0.65) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.65). On average, equities research analysts forecast that Deciphera Pharmaceuticals Inc will post -2.62 EPS for the current year.

A number of research analysts have recently commented on DCPH shares. Guggenheim started coverage on Deciphera Pharmaceuticals in a report on Monday, September 17th. They set a “buy” rating on the stock. BidaskClub lowered Deciphera Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, September 18th. Leerink Swann started coverage on Deciphera Pharmaceuticals in a report on Monday, September 24th. They set an “underperform” rating and a $28.00 price objective on the stock. ValuEngine raised Deciphera Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, October 2nd. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $53.00 price objective on shares of Deciphera Pharmaceuticals in a report on Wednesday, October 3rd. Two analysts have rated the stock with a sell rating, one has given a hold rating and ten have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $42.67.

Hedge funds have recently made changes to their positions in the business. Legal & General Group Plc lifted its position in shares of Deciphera Pharmaceuticals by 55.4% in the 3rd quarter. Legal & General Group Plc now owns 1,647 shares of the company’s stock worth $64,000 after acquiring an additional 587 shares during the period. Bank of America Corp DE lifted its position in shares of Deciphera Pharmaceuticals by 316.1% in the 2nd quarter. Bank of America Corp DE now owns 2,609 shares of the company’s stock worth $103,000 after acquiring an additional 1,982 shares during the period. MetLife Investment Advisors LLC bought a new stake in shares of Deciphera Pharmaceuticals in the 3rd quarter worth approximately $235,000. Rhumbline Advisers bought a new position in shares of Deciphera Pharmaceuticals during the 2nd quarter worth approximately $301,000. Finally, Highland Capital Management LP bought a new position in shares of Deciphera Pharmaceuticals during the 2nd quarter worth approximately $394,000. Institutional investors own 55.04% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Thomas Patrick Kelly Sells 5,000 Shares of Deciphera Pharmaceuticals Inc (DCPH) Stock” was first published by WKRB News and is owned by of WKRB News. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international trademark and copyright legislation. The legal version of this article can be read at https://www.wkrb13.com/2019/01/11/thomas-patrick-kelly-sells-5000-shares-of-deciphera-pharmaceuticals-inc-dcph-stock.html.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors.

Featured Article: Catch-Up Contributions

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply